This segment focuses on the research, development, and clinical evaluation of novel molecular glue degraders (MGDs) for the treatment of various cancers. Research and development activities include identifying and validating protein targets, designing and synthesizing small molecule degraders, and conducting preclinical and clinical studies. The primary technology platform is based on the company's proprietary protein degradation platform. The lead product candidate, MRT-2359, targets GSPT1 in MYC-driven tumors. The goal is to provide more effective and targeted cancer therapies with improved patient outcomes and reduced side effects. Market positioning is based on the development of first-in-class MGDs. Future opportunities include expanding the pipeline to address additional cancer types and exploring combination therapies. Clinical trials are underway to assess the safety and efficacy of MRT-2359. Partnerships with Roche and other organizations support the development and commercialization efforts.

This segment is dedicated to developing MGDs for the treatment of autoimmune and inflammatory diseases. Research and development efforts focus on identifying and validating targets involved in the pathogenesis of these diseases, such as MRT-6160 for systemic and central nervous system autoimmune diseases and MRT-8102 for IL-1?/NLRP3 driven inflammatory diseases. The company utilizes its protein degradation platform to design and develop small molecule degraders that selectively target disease-causing proteins. The aim is to provide therapies that can modulate the immune system and reduce inflammation, leading to improved patient outcomes. Market positioning is based on the development of novel therapies for diseases with high unmet medical needs. Future opportunities include expanding the pipeline to address additional autoimmune and inflammatory conditions. Clinical trials are planned or underway to assess the safety and efficacy of the lead product candidates. Collaborations with other organizations may be pursued to accelerate development and commercialization.